share_log

AbbVie | 8-K: Current report

AbbVie | 8-K: Current report

艾伯維公司 | 8-K:重大事件
美股SEC公告 ·  09/11 03:34

Moomoo AI 已提取核心訊息

On September 6, 2024, AbbVie Inc. announced the approval of an amendment and restatement of the company's By-laws by its Board of Directors, effective immediately. The updated Third Amended and Restated By-laws include a change to the address of the company's registered agent and the removal of section 2.13(D)(iv), which had been challenged in a stockholder class action lawsuit. AbbVie stated that while they believe the provision to be lawful, it no longer holds practical value for the company and defending it is not considered the best use of resources. The full text of the amended By-laws is available as Exhibit 3.1 attached to the Current Report on Form 8-K.
On September 6, 2024, AbbVie Inc. announced the approval of an amendment and restatement of the company's By-laws by its Board of Directors, effective immediately. The updated Third Amended and Restated By-laws include a change to the address of the company's registered agent and the removal of section 2.13(D)(iv), which had been challenged in a stockholder class action lawsuit. AbbVie stated that while they believe the provision to be lawful, it no longer holds practical value for the company and defending it is not considered the best use of resources. The full text of the amended By-laws is available as Exhibit 3.1 attached to the Current Report on Form 8-K.
2024年9月6日,艾伯維公司董事會宣佈批准了公司章程的修訂,即刻生效。更新的第三次修訂章程包括公司註冊代理人地址的更改和刪除第2.13(D)(iv)條款,該條款在股東集體訴訟中受到質疑。艾伯維公司表示,儘管他們認爲該條款是合法的,但它對公司不再具有實際價值,並且捍衛它不被視爲最佳資源利用。修訂後的章程的完整文本作爲8-K表格的附件3.1附上。
2024年9月6日,艾伯維公司董事會宣佈批准了公司章程的修訂,即刻生效。更新的第三次修訂章程包括公司註冊代理人地址的更改和刪除第2.13(D)(iv)條款,該條款在股東集體訴訟中受到質疑。艾伯維公司表示,儘管他們認爲該條款是合法的,但它對公司不再具有實際價值,並且捍衛它不被視爲最佳資源利用。修訂後的章程的完整文本作爲8-K表格的附件3.1附上。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息